Market Overview

The global pet cancer therapeutics market size was valued at USD 320.2 Million in 2024 and is expected to reach USD 664.8 Million by 2033. The market is projected to grow at a CAGR of 8.03% during the forecast period of 2025-2033. Growth is driven by rising pet ownership rates, advancements in veterinary medicine, and increased awareness about pet cancer therapeutics.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Pet Cancer Therapeutics Market Key Takeaways

• The global pet cancer therapeutics market was valued at USD 320.2 Million in 2024, with a CAGR of 8.03% forecasted from 2025 to 2033.
• The increasing prevalence of cancer in pets and greater investments by pet owners in advanced therapeutics are major growth drivers.
• Advances in veterinary oncology, including targeted therapies and immunotherapies, have expanded treatment options.
• Veterinary hospitals and clinical pharmacies represent the largest end-user segment due to their role in drug distribution and treatment.
• North America leads the market given its high pet ownership, strong human-animal bond, and robust veterinary healthcare infrastructure.

Sample Request Link: https://www.imarcgroup.com/pet-cancer-therapeutics-market/requestsample

Market Growth Factors

Also influencing demand for advanced cancer therapy is the growing popularity of owning pets with people considering them to be part of the household and willing to provide them treatment for illness or injury (64% of U.S. households own pets).

Over the past three decades, the technical practices for veterinary oncology have improved, including the ability to detect cancers earlier and to develop personalized treatments. Effective use of targeted and immunotherapies has encouraged owners toward seeking specialized veterinary care.

Total veterinary spending on cancer shows pet owners will invest in cancer therapeutics as new treatments become available and effective. It also incentivizes researchers to develop pet cancer treatment.

Market Segmentation

• Therapy:
• Chemotherapy: Dominates the market as a standard treatment targeting rapidly dividing cancer cells, effective for various cancers like lymphoma and mast cell tumors, with recent improvements reducing side effects.
• Radiation Therapy
• Immunotherapy
• Combination Therapy
• Others
• Animal Species:
• Dogs: Hold the largest market share due to high susceptibility to cancers such as lymphoma and melanoma; dogs serve as valuable models in veterinary oncology research.
• Cats
• Others
• Cancer Type:
• Mast Cell Cancer: Represents the most prevalent cancer type; common skin cancer in dogs with variable behavior, driving demand for specialized therapeutics.
• Lymphoma
• Melanoma
• Mammary and Squamous Cell Cancer
• Others
• End User:
• Veterinary Hospitals and Clinical Pharmacies: The largest segment offering centralized access to specialized cancer drugs and therapies, ensuring personalized care and accurate drug dispensing.
• Retail Pharmacies
• Online Pharmacies
• Others

Regional Insights

North America leads the global pet cancer therapeutics market due to high pet ownership rates, strong human-animal bonds, advanced veterinary oncology research, and well-established healthcare infrastructure. This region benefits from collaborative clinical trials and personalized pet care trends, collectively driving market growth and dominance.

Recent Developments & News

• In July 2023, Boehringer Ingelheim International GmbH received FDA approval for NexGard PLUS, a chewable tablet protecting dogs from internal and external parasites.
• In December 2022, Elanco Animal Health Incorporated received FDA approval for Bexacat, the first oral treatment for feline diabetes.
• In November 2021, ELIAS Animal Health LLC obtained exclusive in-license for Oncolytic Vaccinia Virus Treatment targeting cancer cells in pets.

Key Players

• AB Science
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• ELIAS Animal Health LLC
• Karyopharm Therapeutics
• Pfizer Inc.
• Regeneus Ltd.
• Rhizen Pharmaceuticals AG
• Torigen Pharmaceuticals Inc.
• VetDC Inc.
• Virbac
• Zoetis Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=4472&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302